Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
“Second Primary Malignancy (SPM) is not a phenomenon of cancer recurrence or metastasis, but it is suffering from another cancer (different from first primary malignancy)”
The highest priority of all newly diagnosed cancer patients is to cure or at least reach complete remission aka cancer-free status. Unfortunately, newly diagnosed cancer patients like me, don’t know that the more toxicity they undergo, the greater their risk of a second primary malignancy.
Chemotherapy and radiation can cause second primary cancers.
My guess is that newly diagnosed cancer patients approve aggressive therapies such as an autologous stem cell transplantation thinking that aggressive therapies give them their greatest chance for cure or a long remission. This is what I thought when I was told about a relatively new procedure called ASCT.
The reality of aggressive therapy is more nuanced and must be understood my newly diagnosed cancer patients.
Chemotherapy and radiation therapy are two of the most common treatments for cancer. While they can be highly effective in killing cancer cells, they also have the potential to cause damage to normal cells in the process. This can lead to a range of side effects, including the potential development of a second primary malignancy.
The fact is evidence-based non-conventional therapies such as curcumin, omega-3 fatty acids, etc. can reduce the risk of a second primary malignancy.
Are you a cancer survivor who has undergone aggressive toxicity? To learn more about an anti-cancer lifestyle contact me at David.PeopleBeatingCancer@gmail.com.
David Emerson
“We conducted a retrospective study identifying patients over the age of 18 who were diagnosed with SPM from the 16 most common cancer sites between 2000 and 2013 from Surveillance, Epidemiology, and End Results data. Cox proportional hazards regression was used to analyze the relationship between different factors associated to the prognosis of SPM. Standard incidence rate of multiple primary (MP-SIR) was also calculated…
Conclusions- With the advancement of medical standards, the survival time of cancer patients is prolonged, but the occurrence of SPM is also increasing, and the prognosis is not optimistic. More attention needs to be invested in the prevention and treatment of SPM…
“Lymphoma patients who receive high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) have an increased risk of second primary malignancy…
In this population-based study, researchers examined data from 803 patients with aggressive lymphoma who received high-dose chemotherapy and autologous HSCT during 2001-2017. These patients were compared to 4015 matched control individuals from the general population…
Over a median follow-up of 7.76 years, the incidence of second primary malignancies was significantly higher in the lymphoma patients than in the matched control individuals — 16% and 11%, respectively…
Yang et al.reported that SPMs are common in cancer patients with an overall cumulative incidence of 14% at 25 years of follow-up (10)…
Second primary malignancy (SPM) is not a phenomenon of cancer recurrence or metastasis, but it is suffering from another cancer [different from first primary malignancy (FPM)] (7,8)…
These findings have “implications for clinical practice and patient counseling, emphasizing the need for careful consideration of the potential risks and benefits of this treatment in patients with lymphoma with the availability of other chemotherapy-free therapies,” the researchers wrote.”
Newswise — (MEMPHIS, Tenn. – October 02, 2023) The population of childhood cancer survivors in the U.S. is increasing, with an overall childhood cancer survival rate greater than 85% five years after diagnosis. However, survivors can still be at increased risk of various health conditions, including second cancers. Using data from the Childhood Cancer Survivor Study (CCSS) and the St. Jude Lifetime Cohort Study (St. Jude Life), scientists at St. Jude Children’s Research Hospital have identified a genetic explanation for why a small proportion of survivors are more likely to develop second cancers and why they may be more severe or deadly…
The St. Jude group showed that survivors with pathogenic (damaging) genetic variants in specific genes, called cancer-predisposing variants, are at an increased risk of developing second, or subsequent, cancers as adults, and those cancers are more likely to be severe and deadly…
Cancer prevention in adult childhood cancer survivors
The total number of childhood cancer survivors who develop second or subsequent cancers is small (<10% based on current studies), and the percentage of survivors who carry cancer-predisposing variants is low (~6%). Together, these factors have made it extremely challenging to study and understand the genetic risks for second cancers and their outcome in this population. To reach statistically meaningful results, Wang and his collaborators combined whole genome/exome sequencing and clinical data from over twelve thousand survivors of childhood cancer. The study combined data from North America’s two largest survivorship studies, the CCSS and St. Jude LIFE cohorts.
These variants are part of the inherited, or germline, DNA that people are born with. This means they can be detected in children when they are first diagnosed with childhood cancers, arming survivors with the knowledge they need to lower their risk later in life.